These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 18952826

  • 1. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 2. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 3. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
    Shoji-Hosaka E, Kobayashi Y, Wakitani M, Uchida K, Niwa R, Nakamura K, Shitara K.
    J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
    [Abstract] [Full Text] [Related]

  • 4. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 6. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 7. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.
    Edberg JC, Kimberly RP.
    J Immunol; 1997 Oct 15; 159(8):3849-57. PubMed ID: 9378972
    [Abstract] [Full Text] [Related]

  • 8. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
    Isoda Y, Yagi H, Satoh T, Shibata-Koyama M, Masuda K, Satoh M, Kato K, Iida S.
    PLoS One; 2015 Oct 15; 10(10):e0140120. PubMed ID: 26444434
    [Abstract] [Full Text] [Related]

  • 9. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
    Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J.
    Proc Natl Acad Sci U S A; 2011 Aug 02; 108(31):12669-74. PubMed ID: 21768335
    [Abstract] [Full Text] [Related]

  • 10. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
    Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K.
    J Mol Biol; 2007 May 04; 368(3):767-79. PubMed ID: 17368483
    [Abstract] [Full Text] [Related]

  • 11. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):93-103. PubMed ID: 16236307
    [Abstract] [Full Text] [Related]

  • 12. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 13. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
    Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K.
    J Mol Biol; 2004 Mar 05; 336(5):1239-49. PubMed ID: 15037082
    [Abstract] [Full Text] [Related]

  • 14. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.
    Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula JT.
    J Proteome Res; 2011 Jul 01; 10(7):3031-9. PubMed ID: 21561106
    [Abstract] [Full Text] [Related]

  • 15. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.
    Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P.
    J Biol Chem; 2006 Feb 24; 281(8):5032-6. PubMed ID: 16330541
    [Abstract] [Full Text] [Related]

  • 16. Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.
    Scallon B, McCarthy S, Radewonuk J, Cai A, Naso M, Raju TS, Capocasale R.
    Int Immunopharmacol; 2007 Jun 24; 7(6):761-72. PubMed ID: 17466910
    [Abstract] [Full Text] [Related]

  • 17. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Biochem; 2006 Sep 24; 140(3):359-68. PubMed ID: 16861252
    [Abstract] [Full Text] [Related]

  • 18. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
    de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D, von dem Borne AE.
    J Immunol; 1996 Apr 15; 156(8):2948-55. PubMed ID: 8609432
    [Abstract] [Full Text] [Related]

  • 19. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 20. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M.
    J Biotechnol; 2007 Jun 30; 130(3):300-10. PubMed ID: 17559959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.